Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can scans and blood tests forecast who recovers after a brain bleed?

NCT ID NCT07882784

Knowledge-focused Sponsor: University Medical Centre Maribor Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 20, 2026 · Last updated Oct 21, 2026 · Updated 1 time

Summary

A spontaneous intracerebral hemorrhage is a serious type of stroke caused by bleeding inside the brain. Doctors have limited tools to predict how an individual patient will recover. This study follows 300 adults treated at three hospitals in Slovenia and Austria from the acute phase through 12 months. Researchers collect clinical exams, brain scans, routine lab results, and blood samples for markers of brain injury and inflammation, then check survival, function, pain, and quality of life at 6 and 12 months. The goal is to build a model that combines these measures to estimate a patient's functional outcome a year later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If it works, the model could help doctors give families a clearer picture of likely recovery after a brain bleed and guide rehabilitation planning.
What could go wrong
This is an observational study, so it cannot prove that any treatment works. A prediction model built from 300 patients at three hospitals may not fit patients elsewhere, and it may not predict outcomes accurately enough to guide care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive adults with acute spontaneous (non-traumatic) intracerebral haemorrhage admitted to stroke units, neurology wards, neurosurgical units or intensive care units of three hospital centres in Slovenia and Austria.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Acute spontaneous (non-traumatic) intracerebral haemorrhage confirmed by non-contrast CT or MRI * Admission during the acute phase of haemorrhage to one of the participating centres * Written informed consent from the patient or, if the patient lacks capacity, consent from a legally authorised representative Exclusion Criteria: * Intracerebral haemorrhage secondary to head trauma * Haemorrhage due to an intracranial neoplasm * Isolated subarachnoid haemorrhage or another primary type of intracranial haemorrhage * Expected survival of less than 24 hours due to non-neurological comorbidity * End-of-life care decision already made at presentation * Withdrawal of consent or major protocol violation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemorrhagic stroke are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cerebral Small Vessel Diseases Charcot-Marie-Tooth disease type 1F hemorrhagic stroke intracerebral hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemorrhagic stroke Intracerebral hemorrhage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Klinikum Klagenfurt am Wörthersee

    Klagenfurt, 9020, Austria

  • LKH-Universitätsklinikum Graz, Medical University of Graz

    Graz, 8036, Austria

  • University Medical Centre Maribor, Department of Neurology

    Maribor, 2000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.